Pemafibrate

From Wikipedia, the free encyclopedia
Pemafibrate
Pemafibrate.svg
Clinical data
Trade namesParmodia
Other namesK-13675
Routes of
administration
Oral
Identifiers
  • (2R)-2-[3-({1,3-Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid
CAS Number
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30N2O6
Molar mass490.556 g·mol−1
3D model (JSmol)
  • CC[C@H](C(=O)O)Oc1cccc(c1)CN(CCCOc2ccc(cc2)OC)c3nc4ccccc4o3
  • InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
  • Key:ZHKNLJLMDFQVHJ-RUZDIDTESA-N

Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.[1]

On 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1 mg tablets.[2]

References[edit]

  1. ^ Yamashita S, Masuda D, Matsuzawa Y (January 2020). "Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases". Current Atherosclerosis Reports. 22 (1): 5. doi:10.1007/s11883-020-0823-5. PMC 6978439. PMID 31974794.
  2. ^ Pemafibrate, pharmacodia.com